New drug cocktail aims to boost pancreatic cancer surgery success
NCT ID NCT07436741
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether adding the targeted drug surufatinib to standard chemotherapy before surgery helps more patients with high-risk pancreatic cancer have their tumors completely removed. About 106 adults with resectable or borderline resectable pancreatic cancer will be randomly assigned to receive either surufatinib plus chemo or chemo alone before and after surgery. The main goal is to see if the combination leads to a higher rate of clean surgical margins (R0 resection).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
surufatinib (a targeted cancer drug) combined with gemcitabine and nab-paclitaxel chemotherapy
What this could lead to
If successful, this could offer a more effective pre-surgery treatment to shrink pancreatic tumors, making complete removal more likely and potentially improving long-term outcomes.
What could go wrong
This is an early-stage Phase 3 trial with only 106 participants, so results may not apply to all patients. Adding surufatinib to chemo could increase side effects, and the treatment may not improve survival or cure the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact